TERBISIL PILLS 250MG

Composition

1 pill contains Terbinafine 250 mg

Packing

28 pcs.

Mechanism of action

Terbisil - antifungal medication. Terbinafine is an allylamine derivative. It has a wide range of antifungal action. In therapeutic concentrations, terbinafine has a fungicidal effect against dermatophytes, yeast-like fungi and some dimorphic fungi. Activity against yeast fungi, depending on their species, can be fungicidal or fungistatic.
Terbinafine specifically inhibits the early stage of biosynthesis of sterols in the cell of the fungus by inhibiting the enzyme squalene epoxidase in the cell membrane of the fungus. This leads to a deficiency of ergosterol and to the intracellular accumulation of squalene, which causes the death of the fungal cell. Squalene epoxidase does not belong to the cytochrome P450 system; therefore, terbinafine does not affect the metabolism of hormones or other drugs.

Indications and usage

- onychomycosis;
- mycosis of the skin;
- heavy common mycoses (body, legs, feet);
- mycosis of the scalp caused by dermatophytes.

Contraindications

Hypersensitivity to the drug; pregnancy; lactation (breastfeeding); children's age up to 2 years.

Pregnancy and Breastfeeding

Due to the fact that data on the safety of terbinafine use in pregnant women are not available, Terbisil in this category of patients is used only in cases where the expected positive effect outweighs the potential risk.
Terbinafine is excreted in breast milk, so the use of the drug during lactation is contraindicated.

Dosage and administration

The duration of therapy is determined by the nature and severity of the disease. Irregular use or premature discontinuation of treatment leads to a relapse of the disease.
In children over 2 years old 125mg pills are used to treat mycosis of the scalp. Data on the use of the drug in children under 2 years of age (or children weighing less than 12 kg) is not available.
Terbisil prescribed 1 time / day. A single dose depends on the body weight of the child.
For adults appoint 250 mg 1 time / day.
The duration of effective treatment is 2-12 weeks. The optimal clinical effect is observed several months after mycological cure and cessation of therapy.

Adverse reactions

Gastrointestinal: often - a feeling of fullness in the stomach, loss of appetite, dyspepsia, nausea, mild abdominal pain, diarrhea; rarely, disturbances or loss of taste (recovery occurs within a few weeks after stopping treatment); in some cases - cholestasis, jaundice, hepatitis (although the causal relationship of these disorders with the administration of Terbisil has not been established, in case of development of hepatobiliary dysfunction, drug treatment should be canceled).
Hemic and lymphatic: in some cases - neutropenia, thrombocytopenia.
Allergic reactions: often - rash, urticaria; in some cases - Stevens-Johnson syndrome, toxic epidermal necrolysis (with the development of progressive skin rash, treatment with Terbisil should be discontinued).

Special notes

It should be borne in mind that if a patient has abnormal liver function (weakness, nausea of ​​unclear etiology, lack of appetite, jaundice, dark urine or lightening feces) during treatment with Terbisil, the patient should be discontinued.
During treatment, it is necessary to control the level of hepatic transaminases.

Drug Interactions

Terbisil has a slight ability to slow down or increase the clearance of drugs that are metabolized by the cytochrome P450 isoenzymes (cyclosporine, tolbutamide, oral contraceptives). Terbinafine excretion can be accelerated by drugs that induce the induction of microsomal liver enzymes (rifampicin). Drugs that inhibit cytochrome P450 isoenzymes (cimetidine) slow down the excretion of terbinafine. If necessary, the simultaneous use of these drugs may require dose adjustment Terbisil.

Overdosage

Symptoms: nausea, vomiting, lower abdominal pain.
Treatment:gastric lavage followed by the use of Activated carbon. If necessary, conduct symptomatic therapy.

Store in a dark place at a temperature of from 15 ° to 30 ° C.